COLUMBIA, Md. - Marylandian -- Precision Antibody, a leading provider of custom monoclonal antibody development services, is pleased to announce its participation in Antibody Engineering & Therapeutics: Accelerating Tomorrow's Antibody Therapeutics Today, taking place December 14–17, 2025, at the Marriott Marquis San Diego, California.

Hosted by Informa Connect, Antibody Engineering & Therapeutics is one of the most influential global events dedicated to advancing antibody discovery, engineering, and therapeutic development. The conference brings together industry leaders, researchers, and innovators shaping the future of biologics and antibody-based medicines.

Precision Antibody will attend the event to engage with the global antibody community and highlight its expertise in delivering high-quality, application-ready monoclonal antibodies that accelerate drug discovery, biomarker validation, and translational research.

More on Marylandian

• Sharpe Automotive Redefines Local Car Care with "Transparency-First" Service Model in Santee
• The Light Academy: Digital Infrastructure Platform for Family-Directed Education
• Secondesk Launches Powerful AI Tutor That Speaks 20+ Languages
• Automation, innovation in healthcare processes featured at international conference in Atlanta
• A High-Velocity Growth Story Emerges in Marine and Luxury Markets

"This meeting provides an exceptional platform to exchange ideas and collaborate with leaders driving the next generation of antibody therapeutics," said Dr. Serrero. "We look forward to connecting with researchers and partners who share our commitment to scientific rigor and antibody performance."

As biomarker antibody specialists, Precision Antibody has a strong track record of success in developing high-quality biomarker antibodies for oncology and precision medicine applications. The company is also a proud contributor to the National Cancer Institute's (NCI) Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies that are widely used in cancer biomarker research.

Attendees of Antibody Engineering & Therapeutics 2025 are invited to connect with the Precision Antibody team in San Diego to learn how its custom monoclonal antibody development platform supports reliable, reproducible, and high-impact research outcomes.

About Precision Antibody

More on Marylandian

• $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway
• Peernovation 365 is Now Available
• Snap-a-Box Brings Texas' First Robot-Cooked Chinese Takeout to Katy–Fulshear
• UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
• Maryland Spay and Neuter Grants Program Request for Proposals, FY27 Grant Cycle

Founded in 2000, Precision Antibody is a U.S.-based biotechnology company specializing in the rapid development of custom monoclonal antibodies. Known for delivering antibodies that work "right the first time," the company supports pharmaceutical, biotech, academic, and government researchers worldwide. With a proven track record in biomarker antibody development and contributions to the NCI's Clinical Proteomic Technologies for Cancer (CPTC) program, Precision Antibody is recognized for setting benchmarks in antibody quality and reliability. In 2025, the company was honored as the Best Monoclonal Antibody Development Company, reinforcing its leadership and commitment to advancing diagnostics, therapeutics, and translational research through high-performance, royalty-free antibodies.

Media Contact:
Precision Antibody
Dr. Jun Hayashi
President
Phone: 410-884-4100
Email: info@precisionantibody.com
Website: http://www.precisionantibody.com